Treatment Action Group (TAG) welcomes the report published today by the World Health Organization TB Vaccine Accelerator Council on how to finance global, equitable access to new TB vaccines.
TAG signed onto this letter sponsored by the HIV Legal Network to Canadian Prime Minister Mark Carney about the importance of strong investments in health and community systems as they reinforce global health security, which in turn keeps everyone safe.
Our Research in Action Awards took place on Monday, October 20, and the video is up now!
In March 2025, the National Institute of Allergy and Infectious Diseases (NIAID) began soliciting comments on the future of the four Division of AIDS (DAIDS)-sponsored HIV clinical research networks: ACTG, IMPAACT, HPTN, and HVTN.
A global coalition reacted to two deals announced today to make long acting lenacapavir (LEN-LA), a 6 monthly HIV PrEP (pre-exposure prophylaxis) injection that provides virtually 100% protection against HIV infection, at $40 per person per year in 2027.
On September 16 at 11 am (U.S.) savesaidsresearch.org starts a massive marathon to save AIDS funding.
TAG and the Community Research Advisors Group (CRAG) are happy to introduce the TB Representative Studies Rubric (TB RSR), a new tool that community advisory boards (CABs) can use when designing and reviewing clinical trials protocols. The TB RSR is a 17-item questionnaire that assesses whether TB treatment trials include the types of people who get TB.
2025 TAG Limited Art Edition To purchase this unique work, please use this form.
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
This Hepatitis C virus (HCV) storyboard describes the experience of Sibusiso Dlamini in Tsawne, South Africa. Sibusiso is a young man who began using substances for leisure in high school, and later in life switched to injecting substances for a stronger high.